Adage Capital Partners
VERV

Adage Capital Partners’s Verve Therapeutics VERV Stock Holding History

Adage Capital Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-690,000
Closed -$13.4M – 1000
2022
Q4 		$13.4M Buy
690,000
+150,000
+28% +$3.97M 0.03% 559
2022
Q3 		$18.5M Buy
540,000
+182,763
+51% +$5.83M 0.05% 429
2022
Q2 		$5.46M Hold
357,237
– – 0.01% 789
2022
Q1 		$8.15M Sell
357,237
-10,000
-3% -$286K 0.02% 747
2021
Q4 		$13.5M Sell
367,237
-102,763
-22% -$4.32M 0.02% 609
2021
Q3 		$22.1M Buy
470,000
+18,320
+4% +$1.08M 0.04% 415
2021
Q2 		$27.2M Buy
+451,680
New +$18.7M 0.05% 365

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners's VERV Position: Q1 2023 in Review

Adage Capital Partners sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 690,000 shares — an estimated $13.4M sold.

Adage Capital Partners first reported a position in VERV in Q2 2021 and held it in 7 quarters. The position peaked at $27.2M in Q2 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

  • Adage Capital Partners reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Adage Capital Partners sold 690,000 Verve Therapeutics shares in Q1 2023, an estimated $13.4M.
  • Adage Capital Partners first reported a position in Verve Therapeutics in Q2 2021 and held it in 7 quarters.
  • Adage Capital Partners's Verve Therapeutics position peaked at $27.2M in Q2 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on Adage Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.